Genticel to Evaluate Roche Molecular Systems’ cobas® HPV Test in Preparation for Phase 3 Program of GTL001
January 07, 2016 08:00 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Appoints Remi Palmantier, PhD, as Chief Scientific Officer to Accelerate Its Development
January 05, 2016 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections
October 29, 2015 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Presents First Half 2015 Financial Results, Operational Progress & Outlook
September 21, 2015 16:01 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of...
US Patent Granted for Use of Genticel's Antigen Delivery Vectors in Combination Therapy to Treat Cancer
September 08, 2015 07:30 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Independent Data Safety Monitoring Board Recommends Continuation per Protocol of Genticel's Phase 2 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate
July 07, 2015 16:05 ET
|
Genticel S.A.
Half of the 236 vaccinated patients have reached the 12-month follow-up milestone
Patient and physician engagement remains very strong with 98% retention rate*
PARIS and TOULOUSE, France,...
Genticel Receives FDA Clearance of IND Application for US Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-Class HPV Therapeutic Vaccine Candidate
June 16, 2015 08:00 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, June 16, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, Its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform
June 01, 2015 08:00 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, June 1, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
Genticel to Present Further Promising Pharmacology In-Vivo Results of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015
April 20, 2015 13:00 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, April 20, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
Genticel Strengthens Management Team and Appoints Valerie Leroy as Senior Director, Corporate Communications and Investor Relations
April 09, 2015 16:58 ET
|
Genticel S.A.
PARIS and TOULOUSE, France, April 9, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...